Upon completion of the research studies, the agreement provides Cerner an option for exclusive licensing of University of New Mexico Health Sciences Center’s (UNMHSC) technology for clinical and commercial use worldwide. This sponsored research agreement is said to be a clear opportunity for Cerner and UNMHSC to make a difference for people who could benefit from this new type of inhaler technology.
Douglas McNair, senior vice president for clinical research at Cerner, said: “Based upon its impressive capabilities for dispersal of particles with only small inspiratory effort, we believe UNMHSC’s DPI technology can become an important addition to the therapeutic armamentarium, especially for indications that affect children and the elderly.”